Geldanamycin

Pricing Availability   Qty
Cat.No. 1368 - Geldanamycin | C29H40N2O9 | CAS No. 30562-34-6
Description: Selective Hsp90 inhibitor
Chemical Name: 9,13-Dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9-carbamate
Purity: ≥98% (HPLC)
Datasheet
Citations (5)
Reviews (1)
Literature (3)

Biological Activity

Selectively inhibits heat shock protein 90 (Hsp90). Binds to the ATP site of Hsp90 (Kd = 1.2 μM) and inhibits its chaperone activity. Consequently inhibits activities of oncogenic kinases (e.g. src, Raf), p53 and steroid receptors. Demonstrates antiproliferative effect on breast cancer stem-like cells.

Technical Data

M. Wt 560.64
Formula C29H40N2O9
Storage Desiccate at -20°C
Purity ≥98% (HPLC)
CAS Number 30562-34-6
PubChem ID 13017912
InChI Key QTQAWLPCGQOSGP-PHLMVCJGSA-N
Smiles O=C1C(OC)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C/C=C(C)/C2=O)C(C(N2)=C1)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 5.61 10

Preparing Stock Solutions

The following data is based on the product molecular weight 560.64. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 17.84 mL 89.18 mL 178.37 mL
0.5 mM 3.57 mL 17.84 mL 35.67 mL
1 mM 1.78 mL 8.92 mL 17.84 mL
5 mM 0.36 mL 1.78 mL 3.57 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Cardenas et al (1998) Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 16 427 PMID: 9807840

Roe et al (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanomycin. J.Med.Chem. 42 260 PMID: 9925731

Whitesell et al (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc.Natl.Acad.Sci.U.S.A. 91 8324 PMID: 8078881

Lee et al (2012) Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie. 94 1382 PMID: 22445681


If you know of a relevant reference for Geldanamycin, please let us know.

View Related Products by Product Action

View all Hsp90 Inhibitors

Keywords: Geldanamycin, Geldanamycin supplier, Selective, Hsp90, inhibitors, inhibits, Heat, Shock, Protein, 90, antibiotics, Antibiotics, Stem, Cell, Signaling, Cancer, Cells, 1368, Tocris Bioscience

5 Citations for Geldanamycin

Citations are publications that use Tocris products. Selected citations for Geldanamycin include:

Yang et al (2018) NudCL2 is an Hsp90 cochaperone to regulate sister chromatid cohesion by stabilizing cohesin subunits. Cell Mol Life Sci PMID: 30368549

Barker et al (2006) Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Neuroscience 34 1148 PMID: 16504968

Young et al (2015) A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. BMC Dev Biol 11 113 PMID: 25700737

Chung-Davidson et al (2015) Hsp90 and hepatobiliary transformation during sea lamprey metamorphosis. Nucleic Acids Res 15 47 PMID: 26627605


Do you know of a great paper that uses Geldanamycin from Tocris? Please let us know.

Reviews for Geldanamycin

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Geldanamycin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Geldanamycin was used in resistance experiments.
By Anonymous on 02/27/2019
Species: Human

Geldanamycin was used in resistance experiments. We investigated the Hsp90 family protein (HtpG) of the organism that makes GdA, S. hygroscopicus.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.